The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00640016




Registration number
NCT00640016
Ethics application status
Date submitted
13/03/2008
Date registered
20/03/2008
Date last updated
31/01/2017

Titles & IDs
Public title
A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma
Scientific title
A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354
Secondary ID [1] 0 0
2007-002090-31
Secondary ID [2] 0 0
CAT-354-0603
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Placebo
Other interventions - CAT-354 1 mg/kg
Other interventions - CAT-354 5 mg/kg
Other interventions - CAT-354 10 mg/kg

Placebo Comparator: Placebo - Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.

Experimental: CAT-354 1 mg/kg - CAT-354 1 milligram per kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.

Experimental: CAT-354 5 mg/kg - CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.

Experimental: CAT-354 10 mg/kg - CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56


Other interventions: Placebo
Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.

Other interventions: CAT-354 1 mg/kg
CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.

Other interventions: CAT-354 5 mg/kg
CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.

Other interventions: CAT-354 10 mg/kg
CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Doubling Concentration of Methacholine at Day 28 - Change in doubling concentrations of methacholine was calculated as Log2 PC20 (Visit x) - Log2 PC20 (Baseline), where x was the post-baseline assessment (Day 28) and PC20 was provocative concentration of methacholine causing 20 percent fall in forced expiratory volume in 1 second (FEV1). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Change in doubling concentration was summarized for sub-therapeutic dose (placebo and CAT-354 1 milligram/kilogram [mg/kg]) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.
Timepoint [1] 0 0
Baseline and Day 28
Secondary outcome [1] 0 0
Change From Baseline in Doubling Concentration of Methacholine at Day 56, 84 or Early Termination - Change in doubling concentrations of methacholine was calculated as Log2 PC20 (Visit x) - Log2 PC20 (Baseline), where x was the post-baseline assessment (Day 28) and PC20 was provocative concentration of methacholine causing 20 percent fall in forced expiratory volume in 1 second (FEV1). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Change in doubling concentration was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.
Timepoint [1] 0 0
Baseline, Day 56, 84 or early termination (any time before Day 84)
Secondary outcome [2] 0 0
Forced Expiratory Volume in 1 Second (FEV1) - The FEV1 was maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.
Timepoint [2] 0 0
Predose, 30 minutes and 6 hours post-end of infusion on Day 0, 28 and 56; Day 4, 14, 35, 63, 84 or early termination (any time before Day 84)
Secondary outcome [3] 0 0
Forced Vital Capacity (FVC) - The FVC was volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.
Timepoint [3] 0 0
Predose, 30 minutes and 6 hours post-end of infusion on Day 0, 28 and 56; Day 4, 14, 35, 63, 84 or early termination (any time before Day 84)
Secondary outcome [4] 0 0
Forced Expiratory Volume in 1 Second (FEV1) as Percentage of Forced Vital Capacity (FVC) - Percentage of FEV1 was calculated as (FEV1/FVC)*100. It signified the percentage of the total amount of air exhaled from the lungs during the first second of forced exhalation. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Result was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.
Timepoint [4] 0 0
Predose, 30 minutes and 6 hours post-end of infusion on Day 0, 28 and 56; Day 4, 14, 35, Day 63, 84 or early termination (any time before Day 84)
Secondary outcome [5] 0 0
Asthma Control Questionnaire (ACQ) Total Score - The ACQ is questionnaire that comprises of 7-questions evaluating participant's asthma control. Six self-administered questions assess asthma control over the past week covering nocturnal waking, morning symptoms, activity limitations, shortness of breath, wheezing, and short-acting bronchodilator use; using 7-point ordinal rating scale from 0 (good control) to 6 (poor control). Seventh question is completed by a health professional on forced expiratory volume in 1 second (FEV1) percentage (%) predicted; scale: 0 (greater than [>] 95% predicted) to 6 (less than [<] 50% predicted. Final score is the average score of the 7 questions, with a score range of 0 (well controlled) to 6 (extremely poor controlled). Result was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.
Timepoint [5] 0 0
Baseline, Day 28, 56, 84 or early termination (any time before Day 84)
Secondary outcome [6] 0 0
Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) - The FEV1 was maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.
Timepoint [6] 0 0
Day 0 to 84
Secondary outcome [7] 0 0
Number of Participants With Diary Data - Participants recorded asthma symptoms, use of reliever inhalers (beta-agonist use for symptom relief and as prophylaxis), and morning and evening peak expiratory flow (PEF) measurements in a diary.
Timepoint [7] 0 0
Day 0, 4, 14, 28, 35, 56, 63 to Day and 84
Secondary outcome [8] 0 0
Number of Participants With Exacerbations - Exacerbation was defined as: Mild (determined from diary data) - 2 consecutive days satisfying the same or 1 of the following criteria: any night with awakening(s) due to asthma or morning PEF 20 % or more below baseline where baseline = average of the 10 days before randomization or as-needed medication use of 2 inhalations or more in 24 hours above baseline where baseline = average of the 10 days before randomization. Severe (determined by taking an exacerbation update and history): deterioration of asthma resulting in emergency treatment or hospitalization or need for oral steroids for 3 days or more (as judged by the Investigator).
Timepoint [8] 0 0
Day 0 to Day 84
Secondary outcome [9] 0 0
Morning Peak Flow and Peak Flow Variability - Peak flow is a participant's maximum speed of expiration.
Timepoint [9] 0 0
Day 0 to Day 84
Secondary outcome [10] 0 0
Adult Asthma Quality of Life (QoL) Questionnaire Final Score - The AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants are asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean response to all questions. The 4 domain scores are the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment).
Timepoint [10] 0 0
Day 0, 28, 84 or early termination (any time before Day 84)
Secondary outcome [11] 0 0
Maximum Observed Serum Concentration (Cmax) for CAT-354
Timepoint [11] 0 0
Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56
Secondary outcome [12] 0 0
Minimum Observed Serum Concentration (Cmin) for CAT-354
Timepoint [12] 0 0
Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56
Secondary outcome [13] 0 0
Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC [0 - t]) for CAT-354
Timepoint [13] 0 0
Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56
Secondary outcome [14] 0 0
Accumulation Ratio for CAT-354 (RA) - Accumulation ratio (RA) is calculated for Cmax, Cmin and AUC as RA for Cmax = Cmax (56 - 84)/Cmax (0 - 28); Similarily, RA for Cmin = Cmin (56 - 84)/Cmin (0 - 28) and RA for AUC= AUC (56 - 84)/AUC (0 - 28) where Cmax (0 - 28) and Cmax (56 - 84) are the maximum observed serum concentration after first dose (Day 0 to Day 28) and after third dose (Day 56 to Day 84), respectively; Cmin (0 - 28) and Cmin (56 - 84) are the minimum observed serum concentration after first and third dose, respectively; AUC (0 - 28) and AUC (56 - 84) are the area under the serum concentration time curve over a dosage interval determined after first and third dose, respectively.
Timepoint [14] 0 0
Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56
Secondary outcome [15] 0 0
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) - An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 84 that were absent before treatment or that worsened relative to pre-treatment state.
Timepoint [15] 0 0
Day 0 to 84

Eligibility
Key inclusion criteria
- Signed and dated written informed consent is obtained prior to any study related
procedure taking place

- Women either infertile (example [e.g.], hysterectomized, sterile or post-menopausal
with amenorrhea of least 1 year duration) or who are practicing an acceptable form of
birth control

- Uncontrolled (refractory) asthma despite treatment with a minimum dose of 800
microgram (mcg) beclomethasonedipropionate or equivalent inhaled corticosteroid per
day plus 1 or more additional controller, that is, long-acting beta-agonist,
leukotriene antagonist or theophylline. Oral corticosteroids (not parenteral) as
additional treatment at any dose are acceptable

- A forced expiratory volume in 1 second (FEV1) acceptable for airway
hyper-responsiveness (AHR) challenge tests (greater than 60 percent of predicted
normal) on the challenge days

- A provocative concentration of methacholine causing a 20 percent fall in FEV1 (PC20)
less than 4 milligram per milliliter (mg/mL)

- Aged 18-80 years

- A 12-lead electrocardiogram (ECG) with no-clinically significant abnormalities

- Clinical chemistry, hematology and urinalysis results within the laboratory reference
ranges or deemed not clinically significant by the Investigator

- Body weight of less than 130 kilogram (kg)

- No other clinically significant abnormality on history and clinical examination

- Able to comply with the requirements of the protocol.
Minimum age
18 Years
Maximum age
80 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Experienced a severe exacerbation within 28 days preceding Day -28/-14 to Day 0

- Onset of uncontrolled seasonal allergy symptoms within 28 days preceding Day -28/-14
to Day 0

- Subjects with a history of allergic rhinitis, seasonal allergy or esophagitis must be
optimally controlled and remain on a stable treatment regimen during the study

- Participation in another study within 5 half-lives or 3 months of the start of this
study, whichever is the longer

- Lower respiratory tract infection within 6 weeks of Day -28/-14 to Day 0

- Current smokers or ex-smokers with greater than 10 pack-years

- Blood donation (more than 550 mL) in the previous 2 months

- Excessive intake of alcohol (as judged by the Investigator) or evidence of drug or
solvent abuse

- Subjects with a physician-diagnosis of any other significant lung disease, including a
primary diagnosis of chronic obstructive pulmonary disease or bronchiectasis, or lung
cancer, sarcoidosis, tuberculosis, pulmonary fibrosis and cystic fibrosis

- Concurrent medication from Day -28/-14 to Day 0 (Screening visit) and for the duration
of the study with any of the prohibited medications

- Significant, uncontrolled disease including serious psychological disorders, chronic
renal failure, uncontrolled hypertension

- systolic blood pressure greater than 200 millimeters of mercury (mmHg), or diastolic
blood pressure greater than 100 mmHg, heart disease, psoriasis requiring treatment and
subjects who have had a heart attack or stroke within the 3 months preceding Day
-28/-14 to Day 0, or who have a known aneurysm

- Onset of uncontrolled seasonal allergy symptoms within 28 days preceding Day -28/-14
to Day 0

- Subjects with a history of allergic rhinitis, seasonal allergy or esophagitis must be
optimally controlled and remain on a stable treatment regimen during the study

- Any factor which, in the opinion of the Investigator, would jeopardize the evaluation
or safety or be associated with poor adherence to the protocol (that is, inability to
complete study diary, perform peak expiratory flow (PEF) measurements)

- The subject's primary care physician recommends the subject should not take part in
the study

- Known hypersensitivity to CAT-354 or its components, to the challenge agents used in
the study or to related drugs.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
St. Vincents Hospital, Thoracic Medicine Unit - Darlinghurst
Recruitment hospital [2] 0 0
Respiratory Medicine Department, Mater Adult Hospital, - South Brisbane
Recruitment hospital [3] 0 0
Princess Alexandria Hospital, Dept of Respiratory Medicine - Woolloongabba
Recruitment hospital [4] 0 0
Eastern Clinical Research Unit - Box Hill
Recruitment hospital [5] 0 0
Monash Medical Centre, Dept Respiratory Medicine. - Clayton
Recruitment hospital [6] 0 0
Dep of Respiratory & Sleep Medicine, Western Hospital - Footscray
Recruitment hospital [7] 0 0
Respiratory & Sleep Medicine, Royal Melbourne Hospital - Parkville
Recruitment hospital [8] 0 0
Lung Institute WA, Sir Charles Gardner Hospital - Nedlands
Recruitment hospital [9] 0 0
WA Lung Research, Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
3128 - Box Hill
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3011 - Footscray
Recruitment postcode(s) [7] 0 0
3050 - Parkville
Recruitment postcode(s) [8] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
Germany
State/province [1] 0 0
Berlin
Country [2] 0 0
Germany
State/province [2] 0 0
Bonn
Country [3] 0 0
Germany
State/province [3] 0 0
Frankfurt
Country [4] 0 0
Germany
State/province [4] 0 0
Magdeburg
Country [5] 0 0
Germany
State/province [5] 0 0
Mainz
Country [6] 0 0
Germany
State/province [6] 0 0
Munster
Country [7] 0 0
Germany
State/province [7] 0 0
Rostock
Country [8] 0 0
Germany
State/province [8] 0 0
Treuenbrietzen
Country [9] 0 0
Netherlands
State/province [9] 0 0
Amsterdam
Country [10] 0 0
Poland
State/province [10] 0 0
Bialystok
Country [11] 0 0
Poland
State/province [11] 0 0
Katowice
Country [12] 0 0
Poland
State/province [12] 0 0
Kraków
Country [13] 0 0
Poland
State/province [13] 0 0
Lubin
Country [14] 0 0
Poland
State/province [14] 0 0
Lublin
Country [15] 0 0
Poland
State/province [15] 0 0
Warszawa
Country [16] 0 0
Poland
State/province [16] 0 0
Zgierz
Country [17] 0 0
Poland
State/province [17] 0 0
Lódz
Country [18] 0 0
United Kingdom
State/province [18] 0 0
Belfast
Country [19] 0 0
United Kingdom
State/province [19] 0 0
Birmingham
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Glasgow
Country [21] 0 0
United Kingdom
State/province [21] 0 0
Leicester
Country [22] 0 0
United Kingdom
State/province [22] 0 0
London
Country [23] 0 0
United Kingdom
State/province [23] 0 0
Manchester
Country [24] 0 0
United Kingdom
State/province [24] 0 0
Newcastle upon Tyne
Country [25] 0 0
United Kingdom
State/province [25] 0 0
Newport
Country [26] 0 0
United Kingdom
State/province [26] 0 0
Norwich
Country [27] 0 0
United Kingdom
State/province [27] 0 0
Stevenage, Hertfordshire

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
MedImmune LLC
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Cambridge Antibody Technology
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
PRA Health Sciences
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
To investigate the effects of CAT-354 on airway hyper-responsiveness (AHR) in uncontrolled
asthma.
Trial website
https://clinicaltrials.gov/show/NCT00640016
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Thomas Mayer, M.D.
Address 0 0
PRA Health Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT00640016